A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial.
Valeria MerzCamilla ZecchettoFrancesca SimionatoAlessandro CavaliereSimona CasalinoMichele PavaranaSimone GiacopuzziMaria BencivengaAnna TomezzoliRaffaela SantoroVita FedeleSerena ContarelliIrene RossiSerena GiacomazziMartina PasquatoCristiana PiazzolaStefano MilleriGiovanni de ManzoniDavide MelisiPublished in: Therapeutic advances in medical oncology (2020)
2017-004522-14.